Press Releases

First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center

Panbela Provides Business Update and Reports Q2 2024 Financial Results

Panbela to Host Q2 2024 Earnings Conference Call on 8/13/24

Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial

DSMB Recommended Continuation with No Trial Modification

• DSMB Recommends Continuation without Modification for Third Time
• Safety Review Included 395 Patients
• Interim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate
• Low Event Rate Suggests Potential for Prolonged Survival
• Rapid Enrollment Positions Company for Enrollment Completion by Q1 2025; Earlier Than Expected

Panbela Announces Oral Presentation at Digestive Disease Week (DDW)

Evaluation of the Safety and Efficacy of Eflornithine (Difluoromethylornithine, DFMO) in Patients with Gastric Premalignant Conditions in the High Incidence Areas of Latin America

Panbela Provides Business Update and Reports Q1 2024 Financial Results

Panbela Announces Issuance of New US & Canada Patent for Claims of a Fixed Dose Combination of Eflornithine and Sulindac

Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024

Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week (DDW)

Panbela Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025

Trial’s lower-than-expected event rate suggests improved survival outcomes